Search Results
Your search for s matches 6864 pages
Showing 1551 - 1600Memorial Sloan Kettering Launches Women in Science Endeavor
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor (WiSE) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and ...
Pediatric Hematologist/Oncologist Yoram Unguru, MD, MS, MA, Explains the Economic Origins of Drug Shortages and Other Ethical Issues
Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have markedly reduced mortality rates over the past 5 decades. Yet, along with clinical advances, oncologists and their young patients with cancer face a host of ethical issues, made more...
A Brief Primer on Managing Anxiety in Older Adults With Cancer
Cancer-related anxiety has negative impacts on emotional, physical, and social well-being, with data indicating older patients are likely to remain undiagnosed, leading to poor outcomes. In this installment of The ASCO Post’s Integrative Oncology series, Drs. Trevino, Saracino, and Roth highlight...
First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...
Role of TP53 Mutations on Disease Severity in Myelodysplastic Syndromes
Considered the “guardian of the genome,” TP53 is the most commonly mutated gene in patients with cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells. When TP53 is mutated, the protein made from this gene, called p53, can no longer...
First-Line S-1 Plus Leucovorin and Oxaliplatin vs S-1 Plus Cisplatin in Advanced Gastric Cancer
As reported in The Lancet Oncology by Kang et al, the Japanese-Korean phase III SOLAR trial showed that oral tegafur/gimeracil/oteracil, a combination known as S-1, plus leucovorin and oxaliplatin was associated with a modest but significant improvement in overall survival vs S-1 plus cisplatin in...
Statin Use Linked to Improvement in Survival in Ovarian Cancer
Lipophilic statin use was associated with a reduced risk of dying of epithelial ovarian cancer in a large observational study. Compared with never users, women with epithelial ovarian cancer who were taking any type of statins had a reduced mortality of 40%, and those taking lipophilic statins had...
First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer
In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulted in a median progression-free survival of 9.2 months and a median overall survival of 12.6 months, ...
Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Carolyn J. Anderson, PhD, has been named the 2020 recipient of the Paul C. Aebersold Award. Dr. Anderson is a Professor in the Departments of Medicine, Radiology, Bioengineering, Chemistry, and Pharmacology and Chemical Biology at the University of Pittsburgh in Pennsylvania. The award was...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
Fox Chase Cancer Center Welcomes Two New Staff Members
Fox Chase Cancer Center, part of the Philadelphia-based Temple University Health System, recently announced two new additions to its staff. Shazia K. Nakhoda, MD, a graduate of the Fox Chase–Temple Hematology/Oncology Fellowship Program, joins the center’s Department of Hematology/Oncology in the...
Yale Cancer Center Awarded NIH SPORE Renewal for Lung Cancer Research
Yale Cancer Center researchers were awarded an $11 million grant renewal from the National Institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer. SPORE harnesses the strengths of academic cancer centers by bringing together experts in oncology,...
Expert Point of View: Marcus Noel, MD, and Susan Tsai, MD, MHS
Marcus Noel, MD, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center and MedStar Georgetown University Hospital, Washington, DC, included SWOG S1505 in the presentation of the Gastrointestinal Cancer Highlights during the ASCO20 Virtual Scientific Program. Susan Tsai, MD, MHS, ...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know
Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.
The Importance of Measuring Health-Related Quality of Life in Older Adults
Compared with younger patients, older patients with cancer face unique challenges because many of them have age-related decreases in health-related quality of life. This can be a result of many factors, such as comorbidities, mental health, physical impairment, and financial stressors. A diagnosis...
Common Hypertension Medications May Also Reduce Risk of Colorectal Cancer
Medications commonly prescribed to treat high blood pressure may also reduce the risk of colorectal cancer, according to new research published by Cheung et al in the journal Hypertension. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are often prescribed...
Effect of Medicaid Expansion on Breast Cancer Stage at Diagnosis
In a study reported in JAMA Surgery, Le Blanc et al found that Medicaid expansion under the Affordable Care Act was associated with increased insurance coverage and reduction in rates of diagnosis of breast cancer at later stages. Study Details The study involved data from the National Cancer...
Trends in Policy Coverage for ctDNA Testing
New research published by Douglas et al in JNCCN—Journal of the National Comprehensive Cancer Network examined coverage trends for circulating tumor DNA (ctDNA) testing, also known as liquid biopsy. In the first-ever study to analyze insurance coverage for ctDNA-based panel tests, researchers found ...
Potential Association of Impaired Spermatogenesis and Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Melanoma
In a study reported as a research letter in JAMA Oncology, Scovell et al identified a potential association between the use of immune checkpoint inhibitors and impaired spermatogenesis using autopsy tissue findings in men with a history of metastatic melanoma. Study Details The study involved...
Patricia S. Steeg, PhD, Receives Women in Cancer Research Charlotte Friend Lectureship
The American Association for Cancer Research (AACR) has honored Patricia S. Steeg, PhD, with its 2020 Women in Cancer Research Charlotte Friend Memorial Lectureship. Dr. Steeg, Co-Director of the Office of Translational Resources and Associate Director of the Center for Cancer Research at the...
Oscar Colegio,MD, PhD, Expert on Skin Cancers Linked to Immunodeficiencies, Dies at 47
Oscar Colegio, MD, PhD, the Lawrence P. & Joan Castellani Family Endowed Chair in Dermatology at Roswell Park Comprehensive Cancer Center, Buffalo, New York, died unexpectedly on June 13, 2020, at a family residence in Connecticut. He was 47. Dr. Colegio had relocated to Buffalo when he was...
The Piano
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Cancer Genome Atlas Founding Members and Current Project Team Awarded 2020 AACR Team Science Awards
During its recent Virtual Annual Meeting II, the American Association for Cancer Research (AACR) presented its 2020 Team Science Awards to the founding members and the current project team associated with The Cancer Genome Atlas (TCGA). TCGA began in 2006 as a joint effort between the National...
Do Not Rush to High-Dose Twice-Daily Radiation for Limited Small Cell Lung Cancer
Bjørn Henning Gronberg, MD, PhD, presented a paper at the ASCO20 Virtual Scientific Program reporting astounding positive results favoring higher-dose, twice-daily radiation therapy in limited-stage small cell lung cancer.1 This was a phase II study (large for phase II but small for phase III)...
Prolonged Overall Survival With Autologous-Allogeneic vs Tandem Autologous Transplant in Newly Diagnosed Myeloma
In a pooled analysis reported in Bone Marrow Transplantation,1 Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, and colleagues found that autologous hematopoietic cell transplantation followed by reduced-intensity conditioning allogeneic transplantation (auto-allo) was...
Elderberry
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on...
NCCN Working Group Policy Recommendations
As the 21st Century Cures Act approaches its 4th anniversary, the National Comprehensive Cancer Network® (NCCN®) convened a working group made up of multidisciplinary experts from across the country to analyze current issues related to the 21st Century Cures Act and to develop recommendations for ...
Atezolizumab Plus Bevacizumab for Unresectable or Metastatic Hepatocellular Carcinoma
On May 29, 2020, atezolizumab in combination with bevacizumab was approved for treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.1-3 Supporting Efficacy Data Approval was based on findings in the international, open-label,...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
Expert Point of View: Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD
Two myeloma specialists weighed in on the disappointing findings of SWOG S1211: Suzanne Lentzsch, MD, PhD, Professor of Medicine at Columbia University and Director of the Multiple Myeloma and Amyloidosis Service, and Joshua Richter, MD, Assistant Professor of Medicine, Icahn School of Medicine at...
Elotuzumab Fails to Add Benefit in Newly Diagnosed High-Risk Myeloma
The addition of elotuzumab to a standard three-drug induction regimen did not improve outcomes in patients with high-risk multiple myeloma enrolled in the randomized phase II SWOG S1211 trial, according to findings reported during the ASCO20 Virtual Scientific Program by Saad Zafar Usmani, MD,...
IMbrave150 Trial: Atezolizumab Plus Bevacizumab Improves Survival in Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, of Jonsson Comprehensive Cancer Center, Geffen School of Medicine at the University of California, Los Angeles, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus...
Geriatric Assessment: What Are You Waiting For?
The ASCO20 Virtual Scientific Program was the forum for an unusual but profoundly important event in oncology. Four studies that should be practice-changing were presented.1-4 These studies provided irrefutable evidence that we can improve the quality of life of older patients by reducing toxicity. ...
Responses Achieved With Belantamab Mafodotin in Relapsed or Refractory Myeloma
The antibody-drug conjugate belantamab mafodotin yielded responses as a single agent and in combination with bortezomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma, according to two reports from the DREAMM team at the ASCO20 Virtual Scientific Program.1,2 In the...
AACR Recognizes New 2019–2020 Research Grantees
The American Association for Cancer Research (AACR) has announced its newest class of grant recipients. Fellowships The 2019 Anna D. Barker Fellowship in Basic Cancer Research was awarded to Chaoyun Pan, PhD, of Emory University, Atlanta, and Conghui Yao, PhD, of Harvard Medical School, Cambridge....
Understanding the Underlying Mechanisms of Pain in Patients With Cancer
Pain is among the most difficult medical issues for oncologists to confront, said Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego, during his keynote address at the 2019 Supportive Care in Oncology Symposium. Failure to adequately manage...
Donor Spotlight: GO2 Foundation for Lung Cancer Unifies to Drive Change
In 2019, the GO2 Foundation for Lung Cancer was born from the merger of the Bonnie J. Addario Lung Cancer Foundation and the Lung Cancer Alliance. The marriage of two lung cancer advocacy groups raises the profile of each group’s work and combines considerable resources to combat lung cancer. The...
Insomnia in Adolescent and Young Adult Cancer Survivors
Adolescents and young adults (AYA) who have survived cancer may continue to suffer from insomnia long after treatment ends, interfering with a range of daily activities. In Pediatric Blood & Cancer, Eric S. Zhou, PhD, and Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute,...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
PSMA-Targeted PET/CT Imaging May Be Useful in Biochemically Recurrent Prostate Cancer
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Alpelisib Deemed Effective in Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor
The phase II BYLieve trial indicates the effectiveness of the PIK3CA inhibitor alpelisib in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor. These results...
First-Line Nivolumab Plus Ipilimumab Shows Activity in NSCLC, With or Without Chemotherapy
Advanced non–small cell lung cancer (NSCLC) in patients whose tumors have no EGFR or ALK alterations poses a particular challenge in terms of first-line therapy. The use of nivolumab plus ipilimumab as well as nivolumab/ipilimumab plus two cycles of chemotherapy, respectively, as first-line therapy ...
Phase III BOSTON Study Finds Selinexor Improves Outcomes in Myeloma
When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor significantly improved progression-free survival and response rates, with a lower incidence of peripheral neuropathy, compared with bortezomib/dexamethasone alone, according to results from the global phase III...
Belantamab Mafodotin Shows Activity in Relapsed or Refractory Myeloma
Treatment of relapsed or refractory multiple myeloma yielded responses with the antibody-drug conjugate belantamab mafodotin, both as a single agent and in combination with bortezomib and dexamethasone. Two reports from the DREAMM team expanded on these findings at the ASCO20 Virtual Scientific...
No Survival Benefit from Local Therapy in de Novo Metastatic Breast Cancer Study
Results of the phase III E2108 study indicate that surgery and radiotherapy given after systemic treatment afforded no additional survival benefit among women with newly diagnosed metastatic breast cancer. The practice may, however, reduce locoregional progression of disease, according to a report...
Conference Highlights From the ASCO20 Virtual Scientific Program
The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...
Expert Point of View: David Wise, MD and Celestia S. “Tia” Higano, MD, FACP
“GnRH antagonists have several advantages over GnRH agonists,” explained David Wise, MD, of Perlmutter Cancer Center at NYU Langone Health in New York. “There is no testosterone flare on initiation [as there is with leuprolide], no increase in cardiac toxicity, and faster onset of action. Currently ...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
